Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Axsome Therapeutics Q3 2026 Results: Net Loss of $12.9M, Loss Narrows

Axsome Therapeutics reported total revenues of $259.7 million for the third quarter of 2026, driven primarily by product sales of AUVELITY, SUNOSI, and SYMBRAVO. While the company remains in a net loss position of $12.9 million for the quarter, this represents a significant improvement from the $47.2 million loss in the prior year period as commercial scale increases.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue259.7171.0
Profit before tax-12.8-47.2
Net income-12.9-47.2
EPS (diluted, $ a share)$-0.25$-0.94

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+51.9%
Operating margin-4.3%
Source

10-Q filed with the SEC, NASDAQ: AXSM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Axsome Therapeutics, Inc.: key numbers

Share price
$135.95Close, Nov 17
Market cap
$7.15B
Shares outstanding
52.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Axsome Therapeutics, Inc.

All →
7:06 AM ET 8-K
Financial Results

Axsome Therapeutics Financial Results

Axsome Therapeutics reported Q3 2026 financial results with total net product revenue of $259.7 million, a 52% year-over-year increase driven by strong sales of Auvelity and Sunosi. The company significantly narrowed its net loss to $12.9 million compared to $47.2 million in the prior year period, surpassing a $1 billion annual revenue run rate.

Term
Q3 2026

“Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate. We expect sustained momentum driven by strong underlying demand for Auvelity in major depressive disorder, and continued acceleration of new patient initiations in Alzheimer’s disease agitation.”

Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.